Cue Biopharma, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018; filed March 14, 2019. This is an annual report, not a standalone fourth-quarter report. Cue is a preclinical biopharmaceutical company developing its Immuno-STAT platform; it had not begun clinical trials, dosed patients, or generated product-sales revenue.
Financial results and position
| Metric | FY 2018 / year-end 2018 | FY 2017 / year-end 2017 |
|---|---|---|
| Collaboration revenue | $1.143 million | None |
| Research and development expense | $28.544 million | $18.900 million |
| General and administrative expense | $11.295 million | $4.334 million |
| Total operating expenses | $39.839 million | $23.234 million |
| Net loss | $38.980 million | $23.234 million |
| Net loss per share, basic and diluted | $1.94 | $2.16 |
| Cash, cash equivalents and marketable securities | $39.213 million | $63.534 million in cash and $0.050 million restricted cash |
| Working capital | $34.393 million | $59.718 million |
| Total assets | $45.363 million | $66.954 million |
| Total liabilities | $11.392 million | $5.347 million |
| Stockholders’ equity | $33.971 million | $61.607 million |
- Net cash used in operating activities was $26.411 million, versus $12.141 million in 2017. Investing activities used $20.354 million; financing activities provided $4.182 million, including approximately $4.169 million from LG Chem’s stock purchase.
- Operating and net margins are not meaningful indicators of a commercial business here: revenue was limited to collaboration revenue, while the company remained in development and loss-making.
- The filing reports no debt borrowings. Liabilities primarily included accounts payable, accrued expenses, deferred rent, and research and development contract liabilities.
Changes and significant items
- Revenue began in 2018 from the Merck collaboration; Cue recognized approximately $1.143 million. It recognized no revenue from the LG Chem agreement in 2018.
- Operating expenses increased approximately 71% year over year. R&D rose by approximately $9.644 million, largely reflecting expanded development activity and production of drug product for planned trials. G&A rose approximately $6.962 million, reflecting increased staffing and public-company infrastructure.
- Net loss increased by approximately $15.746 million. Loss per share improved from $2.16 to $1.94, while weighted-average shares outstanding increased to 20.134 million from 10.732 million.
- 2017 R&D included a noncash charge of approximately $5.037 million for shares issued to Einstein under the license agreement. Stock-based compensation was $7.174 million in 2018, compared with $2.775 million in 2017.
- Cash and investments declined from approximately $63.584 million at 2017 year-end to $39.213 million at 2018 year-end. Management said existing resources were expected to fund projected operating requirements for at least the next 12 months, based on current plans.
Outlook, collaborations and risks
- Cue planned to submit an IND for lead candidate CUE-101 and begin clinical trials in the first half of 2019, initially targeting recurrent or metastatic HPV-positive head and neck cancer. These were plans, not achieved milestones as of the filing.
- CUE-101’s preclinical evidence included antigen-specific T-cell activation and expansion, plus activity in a mouse tumor model. The filing cautions that preclinical findings may not predict human safety or efficacy.
- The November 2018 LG Chem agreement provided a $5.0 million nonrefundable upfront payment and approximately $5.0 million in equity investment. Cue may receive up to approximately $400 million in research, development, regulatory and commercial milestones, plus royalties, subject to achievement of conditions. These potential payments are not guaranteed.
- The Merck autoimmune collaboration included a $2.5 million upfront payment and potential development, regulatory and commercial milestones, as well as royalties. Cue recognized revenue over time under its performance obligations; the upfront payment should not be treated as wholly earned revenue.
- Management expected R&D and G&A expenses to continue increasing. Cue stated that additional financing may be needed and that financing might not be available on acceptable terms. The business faces clinical, regulatory, funding, intellectual-property, manufacturing, reimbursement and collaboration risks.
- Operating lease commitments totaled $10.804 million at year-end. Adoption of the new lease standard in 2019 was expected to add a right-of-use asset of approximately $9.692 million and a lease liability of approximately $9.347 million, without a retained-earnings adjustment.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting. The auditor issued an unqualified opinion on the 2018 financial statements; the auditor did not opine on internal-control effectiveness.
Key investor verification points
- Confirm whether CUE-101’s planned IND submission and trial initiation occurred, and review subsequent clinical safety, enrollment and activity data.
- Track cash burn against the stated 12-month runway, including spending growth, later financing, and the timing and terms of any capital raises.
- Review collaboration accounting and cash economics: amounts recognized versus deferred, milestone conditions, cost-sharing obligations, royalty terms and termination rights under the Merck and LG Chem agreements.
- Assess whether preclinical evidence translates into human results and whether CUE-101 manufacturing, regulatory and clinical timelines remain achievable.
- Monitor lease obligations, equity dilution from stock compensation and future financing, and progress in protecting the licensed and company-owned intellectual property.